LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

100.3 1.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

98.45

Massimo

102.91

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.682 49.8
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 367M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+10.72% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	358M 19B
Apertura precedente	98.42
Chiusura precedente	100.3

Notizie sul Sentiment di mercato

By Acuity

23%

77%

70 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

59.52 / 62.66 Supporto e resistenza

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 mag 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mag 2026, 23:46 UTC

Discorsi di Mercato

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mag 2026, 23:33 UTC

Discorsi di Mercato

Gold Rises on Possible Position Adjustments -- Market Talk

11 mag 2026, 22:37 UTC

Discorsi di Mercato

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mag 2026, 22:32 UTC

Utili

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mag 2026, 22:02 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mag 2026, 21:49 UTC

Utili

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mag 2026, 21:42 UTC

Discorsi di Mercato

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mag 2026, 21:23 UTC

Acquisizioni, Fusioni, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mag 2026, 21:12 UTC

Utili

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mag 2026, 21:12 UTC

Utili

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

11 mag 2026, 20:44 UTC

Utili

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mag 2026, 20:43 UTC

Utili

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Rev $136.4M >CLSK

11 mag 2026, 20:30 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Cont Ops EPS $2.24 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Rev $1.6B >STE

11 mag 2026, 20:30 UTC

Utili

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Adj EPS $2.83 >STE

11 mag 2026, 20:22 UTC

Azioni calde

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mag 2026, 19:37 UTC

Utili

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mag 2026, 19:32 UTC

Discorsi di Mercato

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

10.72% in crescita

Previsioni per 12 mesi

Media 109.13 USD 10.72%

Alto 135 USD

Basso 75 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

70 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation